Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms
Amphetamine-related drugs, such as 3, 4-methylenedioxymethamphetamine (MDMA) and
methamphetamine (METH), are popular recreational psychostimulants. Several preclinical …
methamphetamine (METH), are popular recreational psychostimulants. Several preclinical …
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
MA Cenci - Frontiers in neurology, 2014 - frontiersin.org
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's
disease (PD) for over 40 years. However, the response to this treatment changes with …
disease (PD) for over 40 years. However, the response to this treatment changes with …
Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia
T Fieblinger, SM Graves, LE Sebel, C Alcacer… - Nature …, 2014 - nature.com
The striatum is widely viewed as the fulcrum of pathophysiology in Parkinson's disease (PD)
and L-DOPA-induced dyskinesia (LID). In these disease states, the balance in activity of …
and L-DOPA-induced dyskinesia (LID). In these disease states, the balance in activity of …
L-DOPA treatment selectively restores spine density in dopamine receptor D2–expressing projection neurons in dyskinetic mice
Background L-3, 4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an
incapacitating complication of L-DOPA therapy that affects most patients with Parkinson's …
incapacitating complication of L-DOPA therapy that affects most patients with Parkinson's …
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy
C Alcacer, L Andreoli, I Sebastianutto… - The Journal of …, 2017 - Am Soc Clin Investig
Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia),
but can develop uncontrollable movements known as dyskinesia upon treatment with L …
but can develop uncontrollable movements known as dyskinesia upon treatment with L …
G protein-coupled receptor kinases as regulators of dopamine receptor functions
EV Gurevich, RR Gainetdinov, VV Gurevich - Pharmacological research, 2016 - Elsevier
Actions of the neurotransmitter dopamine in the brain are mediated by dopamine receptors
that belong to the superfamily of G protein-coupled receptors (GPCRs). Mammals have five …
that belong to the superfamily of G protein-coupled receptors (GPCRs). Mammals have five …
L-DOPA oppositely regulates synaptic strength and spine morphology in D1 and D2 striatal projection neurons in dyskinesia
Dopamine depletion in Parkinson's disease (PD) produces dendritic spine loss in striatal
medium spiny neurons (MSNs) and increases their excitability. However, the synaptic …
medium spiny neurons (MSNs) and increases their excitability. However, the synaptic …
The signaling and pharmacology of the dopamine D1 receptor
J Jones-Tabah, H Mohammad, EG Paulus… - Frontiers in Cellular …, 2022 - frontiersin.org
The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the
midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive …
midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive …
[HTML][HTML] Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is
characterized by neuroinflammation, dopaminergic neuronal cell death and motor …
characterized by neuroinflammation, dopaminergic neuronal cell death and motor …
The role of dopamine receptors in the neurotoxicity of methamphetamine
S Ares‐Santos, N Granado… - Journal of internal …, 2013 - Wiley Online Library
Methamphetamine is a synthetic drug consumed by millions of users despite its neurotoxic
effects in the brain, leading to loss of dopaminergic fibres and cell bodies. Moreover, clinical …
effects in the brain, leading to loss of dopaminergic fibres and cell bodies. Moreover, clinical …